Chapter 123 Old acquaintances gather at the summit! (Please subscribe)
Like the meeting process list provided by the organizer, the morning meeting was led by three doctors from different hospitals who took the lead in academic sharing.
The first one is Professor Li Mingren from the National Hospital of Singapore. He shared the matters needing attention and case descriptions of kidney transplantation for children under 10 years old.
The second and third people were doctors from "Peking University School of Medicine" and "Royal Melbourne Hospital, Australia" respectively. They shared how to use immunotherapy to delay chronic renal failure and how to reverse early kidney function. decline.
Zhang Yang had some difficulty listening, especially the professional terminology that was difficult to understand for a while, but fortunately with the PPT shared by the doctors, he could barely understand it at least 50% or 60%.
It has to be said that the doctors who were invited to participate were all top-notch people in the industry and were of high quality. Except for Zhang Yang who first attracted everyone's attention when he entered the venue, almost no one paid attention to him throughout the morning.
Zhang Yang also enjoys it.
Soon, the doctor’s sharing session in the morning ended. After a short break after lunch, the new drug sharing session was about to begin at 2 p.m.
Compared with doctors sharing cases in the morning, major pharmaceutical companies are much more free to share new drugs in the afternoon.
All invited pharmaceutical companies can take turns to come on stage to briefly introduce their recent developments. The results of two years of research and development of kidney disease drugs, whether they are in the first or second phase of clinical trials, or some kidney disease drugs that have been launched but have not been fully recognized by the market, can be recommended and promoted on stage.
After all, strictly speaking, most of the funding for the "Kidney Disease Summit" held every two years comes from sponsorships by major pharmaceutical companies.
The doctors are also willing to cooperate.
First of all, everyone’s energy is limited. Doctors are already too busy performing surgeries and outpatient visits, and they don’t have time to pay attention to any new drugs or special drugs that have appeared in the pharmaceutical field;
< br>In addition, there are dozens of new kidney disease drugs approved globally every year, and it is impossible for doctors to understand each one carefully because they do not have so much energy.
Being able to listen to front-line drug information in such a high-level forum is also the most efficient and least labor-intensive way for them to obtain information.
Moreover,
Although every pharmaceutical company can go on stage to promote new drugs in the new drug sharing session, most pharmaceutical companies are considered very efficient if they can develop a good new drug within five years.
Therefore, only a few pharmaceutical companies actually take the stage to promote their new drugs at each summit.
At 1:40, Zhang Yang returned to his seat from the lounge. At this time, the seats for pharmaceutical company representatives on the right side of the conference hall were nearly two-thirds full compared to the empty seats in the morning.
The position of Qingshan Pharmaceutical is in the last row. In the morning, he noticed that the seats in the first row in front were reserved for international pharmaceutical companies such as Novartis, Roche, and GlaxoSmithKline;
The second and third rows are reserved for companies such as Germany's Boehringer Ingelheim (BI), where Fang Hanliang works, which has a certain influence on drugs in the field of kidney disease.
Zhang Yang didn't care. Just as he was quietly waiting for the sharing session to begin, a familiar voice suddenly sounded from behind.
"Zhang, it's you? Are you here in person?"
Before Zhang Yang could react, a familiar yet slightly vague figure appeared in front of him.
It's Lucas from Slaxton Smith.
When GlaxoSmithKline introduced "ITG human myelopoietin" before, he was the one who negotiated the contract with Zhang Yang.
Zhang Yang also has a pretty good impression of Lucas. Lucas is not as cunning as Western capitalists. On the contrary, he comes across as sincere and a good person.
Then he stood up and said with a smile:
"Mr. Lucas, long time no see."
"This is the first time we were invited to participate in such a summit, so I I came here in person, but I didn’t expect to meet you. What about you? Did your company send you to attend?”
"Well, yes."
Lucas looked a little surprised and happy when he saw Zhang Yang. He smiled and said:
"I am the person in charge of our company's Asia region, and it just so happened that I recently I’m also in China, so I dropped by to attend.”
“I didn’t expect to meet you.”
“Haha.”
After saying that, he exchanged a few words with Zhang Yang. Seeing that the meeting at two o'clock in the afternoon was about to start, he left and prepared to walk to his seat in the first row.
But at this moment, another voice suddenly sounded in my ears.
"Zhang!"
"Oh my God! You are here!"
Zhang Yang was stunned for a moment, and then an indescribable smile appeared on his face. This man He didn't like it too much, but his voice was too familiar.
"Mr. Friedman...we meet again."
Friedman stood in front of Zhang Yang and hugged Zhang Yang fiercely.
"Zhang, why didn't you tell me that you were coming to this summit in person? If you had told me that you were coming, I would have definitely been here in the morning."
Zhang Yang did it without leaving any trace. I pushed away Friedman's hug and had to explain again:
"This is the first time we have been invited to participate in this summit, so we came in person."
"Oh."
Friedman was all smiles:
"Welcome to join the kidney disease drug development club."
But as soon as he finished speaking, he suddenly looked startled. , looked at Zhang Yang with surprise and expectation:
"Zhang, you won't tell me that you are also preparing to enter the field of kidney disease and will develop kidney disease drugs, right?"
Zhang Yang did not deny it, but nodded after hesitating for two seconds:
“We do have ideas in this regard.”
“Really?”
In Friedman’s eyes Suddenly there was a flash of light, and Zhang Yang's expression instantly became a little excited!
At this moment, on the main booth in front, a host took a microphone and began to walk towards the middle of the stage.
Friedman knew that the afternoon meeting was about to begin. He looked at the table sign that belonged to his seat in the first row, then looked at the seat next to Zhang Yang, and then quickly ran to the first row in three steps and two steps at a time. Then he picked up the table sign with his name and company on it and returned to Zhang Yang.
"Zhang, I see there is no one around you, is it okay for me to sit next to you?"
Zhang Yang was stunned for a moment, and even Lucas, President of GlaxoSmithKline Asia, stood aside He couldn't help but be stunned.
He looked at Friedman in surprise, but he quickly came to his senses...
He knew that Novartis’ performance has skyrocketed in the past six months due to the introduction of Qingshan Pharmaceutical’s “LivClearX”. As a result, the entire company made a lot of money, and even the stock price increased by 10%!
And just now Zhang Yang admitted that he had the idea to enter the field of kidney disease drug research...
But...
Zhang Yang should just talk briefly. Does Friedman need to be so attentive? Want to take advantage of kidney drugs again?
He shook his head with disdain. Seeing the host below starting to open the afternoon, he no longer hesitated and hurried to the first row to pick up his and "GSK" table tickets, and then Back to the last row.
"Zhang, I see there is no one here. Is it okay for me to sit on your right?"
Zhang Yang looked dumbfounded as Friedman from Novartis and Lucas from GlaxoSmithKline sat next to him.
The two of them ran up and down in surprise, which also attracted the attention of the other ten people present. At the attention of several pharmaceutical company representatives, everyone turned their heads.
When I saw Friedman and Lucas sitting in the last row, respectively, accompanying the president of Qingshan Pharmaceutical, my eyes widened!
You know, the organizer arranged for Mr. Friedman and Mr. Lucas to sit in the C seat in the first row. They didn’t even want the C seat and went to sit in the last row, next to the green yam. The boss of the industry is sitting? !
What's going on?
Fortunately, although everyone was surprised, after the host's opening remarks, the afternoon session of sharing new drugs from pharmaceutical companies officially began.
Before the host asked, a working representative from a pharmaceutical company was already eager to give it a try.
Looking at a blond white man walking on stage, Friedman on the side took the lead in introducing:
"Zhang, this is the vice president of Roche's Asia business. They are currently promoting a product. The improved drug is empagliflozin, a GLT-2 inhibitor used to control diabetic nephropathy." Zhang Yang nodded slightly, looked at the center of the booth, and then heard a clear voice coming from the booth.
"Good afternoon, doctors, I am Richardson from Roche. Three months ago, our latest improved 'empagliflozin' had its indications expanded by the US FDA."
"Everyone knows , before our 'empagliflozin' was mainly used for the treatment of type 2 diabetes, but in recent years, after a large number of clinical applications and our continuous The drug ingredients have been improved, and the latest test results have found that the improved 'empagliflozin' also has an excellent therapeutic effect on kidney disease caused by diabetes..."
"Next, let me show you first. A set of clinical trial data..."
Zhang Yang's eyes immediately followed and landed on the screen behind the conference hall.
Actually, kidney disease is mainly divided into three types.
The first type is hereditary kidney disease, which is related to genes and has fewer patients.
The second type is primary kidney disease, mainly glomerulonephritis, nephrotic syndrome, IGA nephropathy, etc. This type of primary kidney disease is mainly caused by viral (bacterial) infection and poor lifestyle. Caused by habitual or long-term use of drugs that damage the kidneys.
Primary kidney disease is also the most common among all kidney diseases, and most of them occur in young people.
The third type is secondary kidney disease.
Secondary kidney disease is mainly kidney disease caused by diabetes and hypertension. This kind of kidney disease is more difficult to treat, and it can even be said that there are almost no good methods for treatment.
For example, for kidney disease caused by diabetes, one can only control blood sugar and take some kidney-protecting drugs, such as Jinshuibao and Bailing Capsules.
Compared with primary kidney disease, secondary kidney disease mainly affects the elderly with certain underlying diseases.
Zhang Yang listened silently as the medical representative from Roche introduced the drug data on the stage.
It must be said that this improved "empagliflozin" is indeed very effective. According to the clinical data published by Roche, if you continue to take "empagliflozin" when you have stage 2 renal disease, there will be There is a 70% chance that the patient will not develop stage 5 kidney disease, which means he will not develop uremia.
Of course, if you start taking it when you have stage III or IV kidney disease, the effect will naturally be compromised.
Even so, the therapeutic effect of empagliflozin can be said to bring hope to countless patients with kidney disease caused by diabetes.
Empagliflozin also inspired Zhang Yang.
Empagliflozin is a drug approved by the FDA in 2014. After ten years of development and improvement, it has been improved from a hypoglycemic drug to treat diabetes to a drug that can now treat diabetic nephropathy. , which shows that the path of continuous improvement of drugs is feasible.
While he was thinking, he continued to listen to the introduction on the stage. After about ten minutes, when the words fell, Zhang Yang also applauded from the bottom of his heart.
Not only Zhang Yang, but also many of the top doctors participating in the meeting had a strong interest in the latest "empagliflozin". After the introduction, several doctors asked in detail for about seven or eight minutes. This is the complete end of the introduction of "Empagliflozin".
Soon, the second product on the market was a drug for the treatment of primary kidney disease-IGA nephropathy.
Primary nephropathy is a problem with the kidney itself.
For example, sitting for long periods of time, staying up late, holding in urine, urinary tract infections and even colds may cause kidney damage. Once or twice is fine, but long-term this can easily lead to nephritis and cause irreparable damage to the kidneys.
Nephritis, or kidney disease, is actually a problem with the glomeruli.
There are 1 million glomeruli in each kidney of the human body, and two kidneys equal 2 million.
Normally, when the kidneys are working, they only mobilize 1 million glomeruli to filter toxins and metabolites in the human body, and the remaining kidney will be in a resting state.
Such a working state will allow the kidneys to get sufficient rest, which is why the human body only needs one kidney to maintain life.
However, compared with liver tissue, glomeruli can regenerate. The glomeruli cannot be regenerated when they are used up or worn out.
So,
Once protein in urine is found, it means that glomeruli have begun to be damaged. This stage is the process of reducing the number of glomeruli from 2 million to 1 million.
This is called the first stage of kidney disease, which is the period when proteinuria appears for the first time.
At this stage, quickly adjust your living habits, reduce staying up late, smoking, and taking appropriate hormone (anti-inflammatory) drugs. There is a high probability that continued glomerular damage can be controlled.
If no attention is paid to glomerular damage in the first stage of kidney disease, once the number of glomeruli drops to 1 million, the human body will only experience mild symptoms, and even blood indicators will remain normal.
Although the human body relies on 1 million glomeruli to work, due to the compensatory mechanism of the kidneys, the remaining glomeruli will increase the working pressure, that is, increase the filtration flow rate, thereby making up for the lack of quantity.
Until the glomeruli are damaged to less than 800,000, the working limit of the glomeruli has been exceeded. At this time, the glomerular filtration rate begins to fall out of the normal value, reaching the second stage of kidney disease.
so.
The core principle of kidney disease is to preserve glomeruli.
How to maintain glomeruli from sustained damage, or in other words, how to regenerate glomeruli, has become the focus of major pharmaceutical companies in developing kidney disease drugs. Key logic.
The logic of new drugs for the treatment of IGA nephropathy on the stage is the same. It mainly uses drugs to reduce glomerular inflammation, thereby preventing death from glomerulosclerosis and preserving more glomeruli.
The logic here is actually the same as that of "hepatocyte activator" in treating liver cirrhosis.
Zhang Yang was also inspired by what he heard, and then another pharmaceutical company came on stage to introduce its new drug.
He listened with great interest, and Friedman and Lucas on the left and right did not stop. They both knew that Zhang Yang was not very familiar with the pharmaceutical companies and drugs participating in the meeting, so one side on the stage As they talked, the two of them kept supplementing Zhang Yang's information in the audience, which gave Zhang Yang a deeper understanding of these medicines.
About an hour later, four pharmaceutical companies had finished promoting their drugs. Seeing that the booths were empty, Zhang Yang was also thinking about whether he should go up and briefly introduce his "Kidney Toxin Clearance". Dialysis replacement needle.”
Just as he was about to stand up, a man with short blond hair in the second row of seats suddenly stood up and walked towards the booth.
Zhang Yang had no choice but to sit down. At first glance, the man who stood up before him was named Hans. He happened to be from Boehringer Ingelheim (BI Company) in Germany, which is the nephrology company where Dr. Fang Hanliang currently works.
"Zhang, this is Hans from BI Company... But it's strange. Has their new drug been developed?"
"I heard it will be some time before."
Speak The one on the right is Lucas. GlaxoSmithKline is located in the UK and is obviously more familiar with German companies that are also in the EU.
He didn't notice Zhang Yang's movements, but asked curiously.
Zhang Yang did not answer. He looked around and saw Hans walking towards the middle of the booth generously, and then smiled, revealing two big dimples. At the same time,
A low and proud voice came simultaneously.
"Dear doctors from the world's top hospitals, as well as colleagues from top pharmaceutical companies."
"What our BI company brings to you today is a product that is currently under development. There are no reagents in clinical trials. "
"To be precise, this is a historic breakthrough agent that may significantly improve the toxin filtration rate of dialysis patients, thereby improving the quality of life and quality of dialysis patients. Survival time.”
Zhang Yang was stunned when he heard this.
BI Company’s new drug is also targeted at dialysis?
What a coincidence, we met!
......
PS: I was really touched when I woke up early in the morning and saw so many friends voting for me. It turns out that so many readers like this book!
So!
All I can do is write, write, write!
The plot this time is definitely different from the previous ones. It’s not just a show-off, don’t worry!
There will be more in a while! Asking for a monthly ticket!
(End of this chapter)